Cargando…
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors
Autores principales: | Roloff, Gregory W., Wen, Frank, Ramsland, Aubrianna, Artz, Andrew S., Kosuri, Satyajit, Stock, Wendy, Odenike, Olatoyosi, Larson, Richard A., Liu, Hongtao, Godley, Lucy A., Thirman, Michael J., Patel, Anand A., Daugherty, Christopher K., DuVall, Adam S., Nawas, Mariam T., Dworkin, Emily, Wool, Geoffrey D., Gurbuxani, Sandeep, Fitzpatrick, Carrie, Segal, Jeremy P., Wang, Peng, Drazer, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388285/ https://www.ncbi.nlm.nih.gov/pubmed/36655425 http://dx.doi.org/10.3324/haematol.2022.282148 |
Ejemplares similares
-
Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults
por: Patel, Anand Ashwin, et al.
Publicado: (2021) -
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021) -
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
por: Wang, Amy Y., et al.
Publicado: (2018) -
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016) -
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2015)